
Inventia Healthcare Recalls 13,500 Chlorthalidone Bottles Over Dissolution Failures
Inventia Healthcare Limited has voluntarily recalled 13,567 bottles of chlorthalidone 25 mg tablets after the medication failed dissolution testing. This is the second recall for this specific drug by the India-based manufacturer in 2026, following an earlier action in June. The FDA has classified the recall as Class II, indicating that while the risk of serious harm is remote, the product may cause temporary or medically reversible adverse health consequences. Patients are advised to consult their healthcare providers before stopping the medication, as abrupt discontinuation could lead to dangerous spikes in blood pressure.




